Abstract: A method of treating a disease or reducing the development of a symptom of a disease in a subject by administering to the subject an amount of tetranectin protein or a tetranectin peptide agonist effective to treat or reduce development of the disease or disease symptom.
Type:
Grant
Filed:
June 4, 2018
Date of Patent:
September 21, 2021
Assignee:
The Feinstein Institutes for Medical Research
Inventors:
Haichao Wang, Wei Li, Jianhua Li, Kevin J. Tracey
Abstract: Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.
Type:
Grant
Filed:
January 16, 2020
Date of Patent:
August 10, 2021
Assignee:
The Feinstein Institutes for Medical Research
Inventors:
Haichao Wang, Wei Li, Kevin J. Tracey, Ping Wang
Abstract: A fastener includes an elongate fastener body defining a longitudinal axis substantially central thereto. The fastener body has a continuous outer fastener shell laterally surrounding the longitudinal axis. The fastener shell longitudinally separates a fastener head end and a fastener tip end. A tool-engaging feature is provided on the fastener head end. A plurality of teeth are located on the fastener shell and extend substantially laterally outward from the longitudinally axis. The fastener shell is comprised of at least one undulate face and at least one substantially flat face. The plurality of teeth are located only on the undulate faces. Each tooth is longitudinally separated from adjacent teeth along an undulate face. A method of installing the fastener into a receiving structure is also described.
Type:
Grant
Filed:
February 13, 2019
Date of Patent:
June 8, 2021
Assignees:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH, THE GENERAL HOSPITAL CORPORATION B
Abstract: Synthesis of O-benzotriazole and O-imidazole synthons are described. Uses of synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the synthons and uses of azapeptides and other peptidomimetics are also described.
Type:
Application
Filed:
January 7, 2021
Publication date:
May 6, 2021
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: Methods are disclosed for preventing systemic infection or controlling metastases or providing a vaccine adjuvant in a subject, the methods comprising stimulating one or more peripheral nerves innervating one or more lymph nodes of the subject.
Type:
Grant
Filed:
February 8, 2017
Date of Patent:
February 23, 2021
Assignee:
The Feinstein Institutes for Medical Research
Inventors:
Sangeeta S. Chavan, William M. Hanes, Kevin J. Tracey
Abstract: Synthesis of O-benzotriazole and O-imidazole synthons are described. Uses of synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the synthons and uses of azapeptides and other peptidomimetics are also described.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
February 16, 2021
Assignee:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: Devices, systems and methods for stimulating (e.g., noninvasively) a subject's inflammatory reflex are provided to reduce bleed time. The method may include the step of non-invasively stimulating the inflammatory reflex (e.g., the vagus nerve, the splenic nerve, the hepatic nerve, the facial nerve, and the trigeminal nerve) of a subject, such as by mechanical stimulation, in a manner which significantly reduces bleed time in the subject. Devices for non-invasively stimulating the inflammatory reflex may include a movable tip or actuator that is controlled to mechanically stimulate the ear. The devices may be hand-held or wearable, and may stimulate the cymba conchae region of the subject's ear.
Type:
Grant
Filed:
September 26, 2017
Date of Patent:
February 9, 2021
Assignee:
The Feinstein Institutes for Medical Research
Inventors:
Kevin J. Tracey, Howland Shaw Warren, Michael Allen Faltys, Carol Ann Amella, Christopher Czura, Jared M. Huston
Abstract: The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.
Type:
Application
Filed:
May 8, 2020
Publication date:
January 7, 2021
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.
Type:
Grant
Filed:
December 14, 2015
Date of Patent:
December 8, 2020
Assignee:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Inventors:
Kevin J. Tracey, Huan Yang, Yousef Al-Abed
Abstract: Compounds for use in synthesis of peptidomimetic agents; synthesis of peptidomimetic agents; peptidomimetic diagnostic and therapeutic agents; and uses of the compounds and peptidomimetic agents in drug discovery, diagnosis, prevention and treatment of diseases are described.
Type:
Application
Filed:
May 8, 2020
Publication date:
November 12, 2020
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: Synthesis of O-benzotriazole and O-imidazole synthons are described. Uses of synthons in synthesis of azapeptides and other peptidomimetics, azapeptides and other peptidomimetics synthesized from the synthons and uses of azapeptides and other peptidomimetics are also described.
Type:
Application
Filed:
May 8, 2020
Publication date:
November 12, 2020
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: The present invention is related to the use of HMGB1 antagonists, specifically derivatives of K883 in the treatment and/or prevention and/or inhibition of neuropathy pain, and in particular diabetic neuropathy in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.
Type:
Application
Filed:
May 8, 2020
Publication date:
November 12, 2020
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates are described. The protocol features the use of Mitsunobu reaction to alkylate specifically the nitrogen atom close to the acylthiol moiety with alcohols to produce protected mono-substituted thiocarbazates that can be stored for months, activated under mild conditions at low temperature using halonium reagents and integrated orthogonally to make substituted semicarbazides that can be used, e.g., as synthons in synthesis of aza-amino acid conjugates, azapeptides and other peptidomimetics.
Type:
Application
Filed:
May 8, 2020
Publication date:
November 12, 2020
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: The present invention is related to HMGB1 antagonists and, in particular, HMGB1 tetramer peptidomimetics which have been stabilized with at least one azatide linkage, such as K883. The present invention is also related to pharmaceutical compositions comprising HMGB1 antagonists such as K883.
Type:
Application
Filed:
May 8, 2020
Publication date:
November 12, 2020
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: The present invention is related to the use of HMGB1 antagonists in the treatment and/or prevention and/or inhibition of acute lung injury in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists, in particular K883, in an effective amount to treat and/or prevent and/or inhibit this condition.
Type:
Application
Filed:
May 8, 2020
Publication date:
November 12, 2020
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Abstract: Methods are disclosed for treating ovarian tumors and ovarian and pancreatic cancers using computed and normalized relative ratios of plasma levels of phospholipids, particularly lysophosphatidylcholine, lysophosphatidylethanolamine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.
Type:
Application
Filed:
April 7, 2020
Publication date:
October 8, 2020
Applicant:
The Feinstein Institutes for Medical Research
Abstract: Methods and systems are described for detecting the likelihood of patent ductus arteriosus (PDA) in an infant using electrocardiogram and photoplethysmographic pulse signals obtained from the upper body and foot of the infant.
Type:
Application
Filed:
April 14, 2020
Publication date:
July 30, 2020
Applicants:
The Feinstein Institutes For Medical Research, Jerusalem College of Technology
Abstract: The present disclosure relates to systems, methods and devices to monitor, diagnose and/or treat diseases or disorders comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, the calibration phase correlating a plurality of nerve activity measurements from a chronically implanted electrode in a subject with a plurality of concurrent measurements of levels of cytokines and/or glucose in the blood to obtain a functional relationship between blood cytokine and/or glucose levels and vagus nerve activity, and the diagnostic, treatment or monitoring phase analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship to initiate a treatment method.
Type:
Application
Filed:
April 19, 2018
Publication date:
June 11, 2020
Applicant:
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Inventors:
Theodoros Zanos, Todd Levy, Emily Battinelli, Kevin J. Tracey, Chad E. Bouton, Sangeeta Chavan, Harold Silverman